The award recognises Medherant’s rapid progress and innovation in the development of next-generation transdermal drug delivery patches
Medherant, founded by Professor David Haddleton and the University of Warwick in 2015, has created a drug delivery platform, TEPI Patch, designed to address many of the disadvantages of previous transdermal drug delivery patches.
It enables a wider range of drugs to be delivered through the skin, has increased drug loading capacity, and provides a better patient user experience than patches currently on the market.
Medherant has also developed a high-throughput system for assessing the rate of drug delivery from its patches, which enables the company to rapidly test a range of potential formulations for each drug and optimise the final product.
The company is already working with pharmaceutical companies to test their drugs in its TEPI Patch platform.
Nigel Davis, CEO Medherant, said: “This award is validation of the potential of our TEPI Patch technology to revolutionise the transdermal drug delivery sector. We have continued to grow an excellent team and to partner with top companies from around the world as we look forward to progressing our technology further.”
The Coventry Telegraph Business Awards aim to celebrate success, recognise achievement and highlight the innovative people and companies in Coventry and Warwickshire who are putting the region on the map by boosting the economy while making a positive contribution to the local community.